Semaglutide in routine clinical practice: interesting news from real-world evidence

J Endocrinol Invest. 2022 Aug;45(8):1599-1600. doi: 10.1007/s40618-022-01810-w. Epub 2022 May 6.

Authors

G Formoso¹, M G Baroni^{2

3}

Affiliations

¹ Department of Medicine and Aging Sciences, Center for Advanced Studies and Technology (CAST, Ex CeSIMet) G. d'Annunzio University Chieti-Pescara, Chieti, Italy.
² Department of Clinical Medicine, Public Health, Life and Environmental Sciences (MeSVA), University of L'Aquila, L'Aquila, Italy. marcogiorgio.baroni@univaq.it.
³ Neuroendocrinology and Metabolic Diseases, IRCCS Neuromed, Pozzilli, Is, Italy. marcogiorgio.baroni@univaq.it.

PMID: 35524036
DOI: 10.1007/s40618-022-01810-w

No abstract available

Publication types

Letter

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptide-1 Receptor
Glucagon-Like Peptides* / therapeutic use
Glycated Hemoglobin
Humans
Hypoglycemic Agents / therapeutic use
Semaglutide

Substances

Glucagon-Like Peptide-1 Receptor
Glucagon-Like Peptides
Glycated Hemoglobin
Hypoglycemic Agents
Semaglutide